EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 148 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2017. The put-call ratio across all filers is 0.35 and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2020 | $1,763,000 | +6.9% | 36,747 | +2.5% | 0.01% | -12.5% |
Q1 2020 | $1,649,000 | -23.2% | 35,837 | +0.2% | 0.01% | 0.0% |
Q4 2019 | $2,148,000 | +20.0% | 35,749 | +13.0% | 0.01% | +14.3% |
Q3 2019 | $1,790,000 | +5.6% | 31,642 | +4.0% | 0.01% | 0.0% |
Q2 2019 | $1,695,000 | +4.6% | 30,432 | -5.2% | 0.01% | -22.2% |
Q1 2019 | $1,620,000 | +17.7% | 32,085 | -6.1% | 0.01% | 0.0% |
Q4 2018 | $1,376,000 | -40.7% | 34,164 | -0.3% | 0.01% | -40.0% |
Q3 2018 | $2,320,000 | -9.2% | 34,251 | +1.4% | 0.02% | -11.8% |
Q2 2018 | $2,554,000 | +43.7% | 33,762 | +0.1% | 0.02% | +30.8% |
Q1 2018 | $1,777,000 | -1.1% | 33,718 | +0.3% | 0.01% | 0.0% |
Q4 2017 | $1,796,000 | -10.7% | 33,613 | -0.3% | 0.01% | -13.3% |
Q3 2017 | $2,011,000 | -24.8% | 33,717 | -0.5% | 0.02% | -28.6% |
Q2 2017 | $2,673,000 | -5.1% | 33,887 | -0.3% | 0.02% | -8.7% |
Q1 2017 | $2,818,000 | +5.9% | 33,973 | +1.3% | 0.02% | 0.0% |
Q4 2016 | $2,660,000 | – | 33,522 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Park West Asset Management LLC | 1,120,235 | $53,749,000 | 2.66% |
TANG CAPITAL MANAGEMENT LLC | 255,616 | $12,264,000 | 1.19% |
Smith, Graham & Co., Investment Advisors, LP | 158,671 | $7,613,000 | 0.92% |
ARMISTICE CAPITAL, LLC | 282,000 | $13,530,000 | 0.59% |
Capital Impact Advisors, LLC | 35,815 | $1,718,000 | 0.57% |
Matarin Capital Management, LLC | 58,977 | $2,830,000 | 0.56% |
GLOBEFLEX CAPITAL L P | 31,702 | $1,521,000 | 0.39% |
CHARTWELL INVESTMENT PARTNERS, LLC | 200,246 | $9,608,000 | 0.37% |
Stanley-Laman Group, Ltd. | 24,000 | $1,152,000 | 0.28% |
VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 264 | $13,000 | 0.20% |